Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer

被引:9
作者
Fohlin, Helena [1 ,2 ]
Perez-Tenorio, Gizeh [2 ]
Fornander, Tommy [3 ]
Skoog, Lambert [4 ]
Nordenskjold, Bo [2 ]
Carstensen, John [5 ]
Stal, Olle [2 ]
机构
[1] Cty Council Ostergotland, Reg Canc Ctr, SE-58185 Linkoping, Sweden
[2] Linkoping Univ, Dept Clin & Expt Med, Fac Hlth Sci, Div Oncol, S-58183 Linkoping, Sweden
[3] Karolinska Univ Hosp, Karolinska Inst, Dept Oncol, Stockholm, Sweden
[4] Karolinska Univ Hosp, Karolinska Inst, Dept Pathol, Stockholm, Sweden
[5] Linkoping Univ, Dept Med & Hlth Sci, Div Hlth & Soc, S-58183 Linkoping, Sweden
基金
瑞典研究理事会;
关键词
Breast cancer; Akt; Protein kinase B; Oestrogen receptor; Long-term; Prognostic factor; TRANSCRIPTION FACTOR FOXO3A; INSULIN-RESISTANCE; POOR-PROGNOSIS; ROLES; ACTIVATION; INHIBITION; PREDICTS; PATHWAY; FAMILY; POSH;
D O I
10.1016/j.ejca.2012.12.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Akt is a signalling modulator for many cellular processes, including metabolism, cell proliferation, cell survival and cell growth. Three isoforms of Akt have been identified, but only a few studies have concerned the isoform-specific roles in the prognosis of breast cancer patients. The aim of this study was to investigate the prognostic value of v-akt murine thymoma viral oncogene homologue 1 (Akt1) and v-akt murine thymoma viral oncogene homologue 2 (Akt2) in oestrogen receptor positive (ER+) and oestrogen receptor negative (ER-) breast cancer with long-term follow-up. Material and methods: The expression of Akt in tumour tissue was analysed with immunohistochemistry in a cohort of 272 postmenopausal patients with stage II breast cancer. The median follow-up time was 19 years. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using the Cox's proportional hazards model. Results: The risk of distant recurrence was reduced for patients with ER+ tumours expressing Akt2 compared to patients with no Akt2 expression (HR = 0.49, 95% CI 0.29-0.82, p = 0.007). When adjusting for important clinical tumour characteristics and treatment, Akt2 was still an independent prognostic factor (HR = 0.38, 95% CI 0.21-0.68, p = 0.001) and the association remained long-term. The prognostic value of Akt2 increased with higher oestrogen receptor levels from no effect among patients with ER-tumours to 68% risk reduction for the group with high ER-levels (P for trend = 0.042). Akt1 showed no significant prognostic information. Conclusion: Our results indicate that Akt2 expression is associated with a lower distant recurrence rate for patients with ER+ tumours and that this association remains long-term. The prognostic value of Akt2 increases with higher oestrogen receptor expression, motivating further mechanistic studies on the role of Akt2 in ER+ breast cancer. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1196 / 1204
页数:9
相关论文
共 34 条
[1]   AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival [J].
Bacus, SS ;
Altomare, DA ;
Lyass, L ;
Chin, DM ;
Farrell, MP ;
Gurova, K ;
Gudkov, A ;
Testa, JR .
ONCOGENE, 2002, 21 (22) :3532-3540
[2]   Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer [J].
Baselga, Jose ;
Campone, Mario ;
Piccart, Martine ;
Burris, Howard A., III ;
Rugo, Hope S. ;
Sahmoud, Tarek ;
Noguchi, Shinzaburo ;
Gnant, Michael ;
Pritchard, Kathleen I. ;
Lebrun, Fabienne ;
Beck, J. Thaddeus ;
Ito, Yoshinori ;
Yardley, Denise ;
Deleu, Ines ;
Perez, Alejandra ;
Bachelot, Thomas ;
Vittori, Luc ;
Xu, Zhiying ;
Mukhopadhyay, Pabak ;
Lebwohl, David ;
Hortobagyi, Gabriel N. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) :520-529
[3]   Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer [J].
Bostner, J. ;
Waltersson, M. Ahnstrom ;
Fornander, T. ;
Skoog, L. ;
Nordenskjold, B. ;
Stal, O. .
ONCOGENE, 2007, 26 (49) :6997-7005
[4]   Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition [J].
Caffarel, Maria M. ;
Andradas, Clara ;
Mira, Emilia ;
Perez-Gomez, Eduardo ;
Cerutti, Camilla ;
Moreno-Bueno, Gema ;
Flores, Juana M. ;
Garcia-Real, Isabel ;
Palacios, Jose ;
Manes, Santos ;
Guzman, Manuel ;
Sanchez, Cristina .
MOLECULAR CANCER, 2010, 9
[5]   Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ) [J].
Cho, H ;
Mu, J ;
Kim, JK ;
Thorvaldsen, JL ;
Chu, QW ;
Crenshaw, EB ;
Kaestner, KH ;
Bartolomei, MS ;
Shulman, GI ;
Birnbaum, MJ .
SCIENCE, 2001, 292 (5522) :1728-1731
[6]   Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2 [J].
Cicenas, J ;
Urban, P ;
Vuaroqueaux, V ;
Labuhn, M ;
Küng, W ;
Wight, E ;
Mayhew, M ;
Eppenberger, U ;
Eppenberger-Castori, S .
BREAST CANCER RESEARCH, 2005, 7 (04) :R394-R401
[7]   Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity [J].
DeGraffenried, LA ;
Friedrichs, WE ;
Russell, DH ;
Donzis, EJ ;
Middleton, AK ;
Silva, JM ;
Roth, RA ;
Hidalgo, M .
CLINICAL CANCER RESEARCH, 2004, 10 (23) :8059-8067
[8]   Distinct Biological Roles for the Akt Family in Mammary Tumor Progression [J].
Dillon, Rachelle L. ;
Muller, William J. .
CANCER RESEARCH, 2010, 70 (11) :4260-4264
[9]   Akt1 and Akt2 Play Distinct Roles in the Initiation and Metastatic Phases of Mammary Tumor Progression [J].
Dillon, Rachelle L. ;
Marcotte, Richard ;
Hennessy, Bryan T. ;
Woodgett, James R. ;
Mills, Gordon B. ;
Muller, William J. .
CANCER RESEARCH, 2009, 69 (12) :5057-5064
[10]   Akt2 negatively regulates assembly of the POSH-MLK-JNK signaling complex [J].
Figueroa, C ;
Tarras, S ;
Taylor, J ;
Vojtek, AB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (48) :47922-47927